Evidence map›Paper›PMID 34564397›Full record

ArticleMetabolites2021

Increased Fibroblast Growth Factor 21 (FGF21) Concentration in Early Second Trimester Amniotic Fluid and Its Association with Fetal Growth.

Nikolaos Vrachnis, Savvas Argyridis, Dionysios Vrachnis, Nikolaos Antonakopoulos, Georgios Valsamakis, Christos Iavazzo, Dimitrios Zygouris, Nikolaos Salakos, Alexandros Rodolakis, Nikolaos Vlahos and 3 more

Open access · goldAbstract read
In one paragraph

Article in Metabolites, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Nikolaos VrachnisThird Department of Obstetrics and Gynecology, Medical School, National and Kapodistrian University of Athens, Attikon Hospital, 12462 Athens, Greece.ORCID 0000-0001-9067-5308
Savvas ArgyridisDepartment of Obstetrics and Gynecology, Archbishop Makarios III Hospital, Nicosia 2029, Cyprus.
Dionysios VrachnisDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens Medical School, Alexandra Hospital, 11526 Athens, Greece.
Nikolaos AntonakopoulosThird Department of Obstetrics and Gynecology, Medical School, National and Kapodistrian University of Athens, Attikon Hospital, 12462 Athens, Greece.
Georgios ValsamakisSecond Department of Obstetrics and Gynecology, Medical School, National and Kapodistrian University of Athens, Aretaieio Hospital, 11526 Athens, Greece.
Christos IavazzoDepartment of Gynecological Oncology, Metaxa Cancer Hospital, 18537 Piraeus, Greece.
Dimitrios ZygourisThird Department of Obstetrics and Gynecology, Medical School, National and Kapodistrian University of Athens, Attikon Hospital, 12462 Athens, Greece.ORCID 0000-0001-6533-1298
Nikolaos SalakosSecond Department of Obstetrics and Gynecology, Medical School, National and Kapodistrian University of Athens, Aretaieio Hospital, 11526 Athens, Greece.
Alexandros RodolakisFirst Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens Medical School, Alexandra Hospital, 11526 Athens, Greece.
Nikolaos VlahosSecond Department of Obstetrics and Gynecology, Medical School, National and Kapodistrian University of Athens, Aretaieio Hospital, 11526 Athens, Greece.
George MastorakosUnit of Endocrinology, Diabetes Mellitus and Metabolism, Second Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens Medical School, Aretaieio Hospital, 11526 Athens, Greece.
Peter DrakakisThird Department of Obstetrics and Gynecology, Medical School, National and Kapodistrian University of Athens, Attikon Hospital, 12462 Athens, Greece.
Zoi IliodromitiNeonatal Department, National and Kapodistrian University of Athens Medical School, Aretaieio Hospital, 11526 Athens, Greece.
National and Kapodistrian University of Athens · GRArchbishop Makarios III Hospital · CYMetaxa Hospital · GRSt George's, University of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Altered fetal growth, either reduced or exacerbated, is associated with adverse perinatal outcomes. The underlying pathogenetic mechanisms of altered growth remain unclear. Fibroblast growth factor 21 (FGF21) and insulin are both considered to be major regulators of tissue growth and metabolism. The aim of our study was to investigate the association of second trimester amniotic fluid FGF21 and insulin concentrations with fetal growth. The amniotic fluid concentrations of FGF21 and insulin were determined in 80 cases of different fetal growth patterns (SGA-small for gestational age, LGA-large for gestational age, and AGA-appropriate for gestational age fetuses). Both peptides were found to be increased in cases of abnormal fetal growth, reduced growth velocity (SGA), or macrosomia (LGA). Specifically, FGF21 was significantly increased, as higher FGF21 levels were observed in the amniotic fluid of SGA and LGA fetuses compared with AGA fetuses (

Indexed as

amniotic fluidfetal growthfetal growth restrictionfibroblast growth factor 21 (FGF21)insulinsmall for gestational age (SGA)

Identifiers

PMID34564397
PMCPMC8470231
OpenAlexW3196592402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.